Project
MSD-MK-3475 KEYNOTE 937
Ongoing - recruitment active ยท 2019 until 2026
Semela David, Stillhard Roman
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2019
End Date
2026
Financing
Industry
Study Design
Study Phase: Phase 3
Adjuvant treatment of HCC
Population Participants with complete radiological response after surgical resection of Stage IB, II and III HCC per American Joint Committee on Cancer (AJCC) 8th Edition with adaptations based on tumor characteristics as established by the pathology report or complete radiological response after local ablation
Keywords
HCC
Adjuvant Therapy
Labels
liver cancer
Brief description/objective
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and
Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant herapy in Participants ith Hepatocellular Carcinoma and Complete Radiological Response after Surgical esection or Local Ablation (KEYNOTE-937)